<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">SC Ibalizumab Warrants Further Study for Preventing HIV-1 Infection</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-10</style></pages><abstract><style  face="normal" font="default" size="100%">Among the strategies being explored to prevent infection with human immunodeficiency virus type 1 is ibalizumab, a humanized monoclonal antibody that binds to CD4 domain 2 and blocks the entry of HIV-1 into CD4-positive T cells. This article discusses the Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers (TMB-108) [NCT01292174] results of a study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous injections of ibalizumab.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>